Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea
Background and aims: The present study aimed to compare the levels of the inflammatory biomarkers of fibrinogen and high-sensitivity C-reactive protein (hs-CRP) among type 2 diabetic patients treated with empagliflozin and other hypoglycemic drugs. Methods: This cross-sectional study was performed o...
Main Authors: | Pegah Mohaghegh, Mohammad Reza Rezvanfar, Farideh Jalali-Mashayekhi, Zahra Amerei, Mohammad Hosseinzadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Shahrekord University of Medical Sciences
2023-10-01
|
Series: | Journal of Shahrekord University of Medical Sciences |
Subjects: | |
Online Access: | https://j.skums.ac.ir/PDF/jskums-25-189.pdf |
Similar Items
-
Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review
by: Sopak Supakul, et al.
Published: (2022-06-01) -
Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01) -
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01) -
Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
by: Yimin Tu, et al.
Published: (2022-12-01) -
Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
by: Genlong Xue, et al.
Published: (2022-10-01)